Marchetti, Monia
 Distribuzione geografica
Continente #
EU - Europa 205
NA - Nord America 135
AS - Asia 81
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
Totale 424
Nazione #
US - Stati Uniti d'America 127
IE - Irlanda 88
SE - Svezia 36
HK - Hong Kong 32
DE - Germania 24
IT - Italia 23
SG - Singapore 23
IN - India 16
CZ - Repubblica Ceca 12
BE - Belgio 9
CA - Canada 8
GB - Regno Unito 5
FI - Finlandia 4
IR - Iran 3
CH - Svizzera 2
EU - Europa 2
JP - Giappone 2
TR - Turchia 2
TW - Taiwan 2
ES - Italia 1
KR - Corea 1
NG - Nigeria 1
UA - Ucraina 1
Totale 424
Città #
Dublin 86
Hong Kong 32
Chandler 20
Singapore 15
Brno 12
Bremen 10
Lawrence 9
Princeton 9
Boardman 8
Delhi 6
Munich 6
Brussels 5
Aalst 4
Toronto 4
Ashburn 3
Asti 3
Helsinki 3
Novara 3
Turin 3
Chicago 2
Jacksonville 2
Jersey City 2
Kolkata 2
Montreal 2
Mumbai 2
Mülheim 2
New Delhi 2
Newbury Park 2
Ottawa 2
Piemonte 2
San Mateo 2
Tokyo 2
Wilmington 2
Zurich 2
Alba 1
Andover 1
Arona 1
Bonnybridge 1
Cagliari 1
Chuncheon 1
Córdoba 1
Espoo 1
Fairfield 1
Houston 1
Kampong Loyang 1
Lagos 1
Los Angeles 1
Manchester 1
Milan 1
New Haven 1
Newcastle upon Tyne 1
Rāygarh 1
Sacramento 1
Santa Clara 1
Stezzano 1
Vergiate 1
Woodbridge 1
Totale 294
Nome #
FRONTLINE THERAPY FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA: A CRITICAL APPRAISAL OF PUBLISHED NETWORK META-ANALYSES 74
PRIMARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN PATIENTS AFFECTED BY HAEMATOLOGICAL MALIGNANCIES (LYMPHOMA, MULTIPLE MYELOMA, ACUTE LEUKAEMIA): GUIDELINES FORM THE ITALIAN SOCIETY OF HAEMATOLOGY 54
Mental health in migrants contacting the mental health operational unit of the National Institute for Health, Migration and Poverty (NIHMP): preliminary data 47
RISK ASSESSMENT MODELS (RAM) OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH BLOOD CANCERS: A SYSTEMATIC REVIEW 42
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 41
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 39
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 30
Comparative clinical value of pharmacologic therapies for B-cell chronic lymphocytic leukemia: an umbrella analysis 28
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 27
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 27
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 26
Totale 435
Categoria #
all - tutte 3.464
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.464


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 1 1 1 0 1 0 1 0
2021/202245 3 0 1 0 1 1 0 5 1 7 4 22
2022/2023196 11 10 15 3 13 17 7 17 90 0 9 4
2023/2024113 7 6 9 0 9 0 29 2 2 5 19 25
2024/202576 16 8 24 5 10 13 0 0 0 0 0 0
Totale 435